CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
Similar Posts
Businesses with fewer than 1,000 employees made 92% of May hires
If you’ve only been applying for gigs at big companies, you may want to rethink where you’re sending job applications. According to data from the Bureau of Labor Statistics, nearly 93% of hires for privately held companies during May came from US business establishments with fewer than 1,000 employees. Companies with 10 to 49 employees…
Tech news: EY to bring tailored AI solutions via Integrated Solutions portfolio
Agentic AI audit platform AuditFile announced the availability of native apps for iPhone, iPad, Apple Watch, Apple TV, and Apple Vision Pro. From an iPhone or iPad, auditors can manage AI agents, follow their progress, respond when an agent needs more information, and review the resulting work. Push notifications alert the auditor when an agent…
Artificial Intelligence: Alignment 2.0 – A Last Chance To Change The Game
The Existential AI-Race Seeking Rescue From The Drowning It’s T minus 10, Cape Canaveral,1962 – the height of the space race. An astronaut sits atop a NASA rocket with over a hundred tonnes of explosive propellant beneath his seat, contemplating that each component was built by the lowest bidder. Not all of them got away…
I’m 68. Should I spend half my 401(k) to buy a home with a mortgage?
There’s a long checklist when deciding where to live, especially in your retirement years.
Does Billionaire Bill Ackman Know Something Wall Street Doesn’t? He Invested in These 2 Stocks That Have Dropped 33% and 18% Over the Past Year
Key Points During the second quarter, Pershing Square Capital Management loaded up on Netflix and Uber, two stocks that have lagged broader equities over the past year. Both stocks have excellent prospects, despite recent obstacles. 10 stocks we like better than Netflix › Bill Ackman, the founder and CEO of Pershing Square Capital Management, has…
